Ticker
ENTACompany Name
ENANTA PHARMACEUTICALS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Debt to Equity Ratio | Shareholders Equity | Total Liabilities |
---|---|---|---|
6/30/2025 | 2.8 | $ 79.28M | $ 221.75M |
3/31/2025 | 2.45 | $ 93.54M | $ 229.46M |
12/31/2024 | 2.12 | $ 111.82M | $ 236.83M |
9/30/2024 | 1.92 | $ 128.81M | $ 247.84M |
6/30/2024 | 1.68 | $ 148.91M | $ 249.91M |
3/31/2024 | 1.49 | $ 166.11M | $ 247.44M |
12/31/2023 | 1.23 | $ 191.88M | $ 236.62M |
9/30/2023 | 1.13 | $ 216.74M | $ 245.54M |
6/30/2023 | 1.08 | $ 237.82M | $ 257.35M |
3/31/2023 | 0.21 | $ 269.38M | $ 57.07M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Liabilities / Equity
(=) D/E
D/E for ENANTA PHARMACEUTICALS INC is calculated as follows: Liabilities [ $ 30.55M ] / Equity [ $ 455.58M ]
(=) D/E [ 0.07 ]
Minimum
Dec 31, 2020
Maximum
Jun 30, 2025
Average
Median
filtered constituents | 3.3K |
---|---|
min | 0 |
max | 6.06 |
average | 1.4 |
median | 0.98 |
std | 1.31 |